CTI/Baxalta Stung By Partial Hold On Pacritinib Following 'Excess Mortality'
This article was originally published in Scrip
Shares of CTI BioPharma Corp have dropped sharply on news that the US FDA has placed a partial hold on pacritinib, an oral tyrosine kinase inhibitor (TKI) with activity against JAK2 and FLT3 mutations, which is being developed as a treatment for myelofibrosis and is partnered with Baxalta. A rolling NDA submission was completed in January this year.
Register for our free email digests: